-
NMPA Notice on Issuing the Guidelines for On-Site Inspection of the Quality Management Specifications for Online Sales of Medical Devices NMPA Medical Device Supervision [2025] No. 14
2025-11-28
The National Medical Products Administration (NMPA) has organized the formulation of the Guidelines for On-Site Inspection of the Quality Management Specifications for Online Sales of Medical Devices (hereinafter referred to as the "Guidelines").
-
NMPA Notice on Conducting a Pilot Program for Electronic Labeling of Cosmetics GYJZ [2025] No.16
2025-11-28
The National Medical Products Administration (NMPA) has decided to carry out a pilot program for cosmetic electronic labeling in accordance with the Regulations on Supervision and Administration of Cosmetics (hereinafter referred to as the "Regulations"). The relevant matters are hereby notified as follows.
-
Announcement of the NMPA on the Release of the Good Manufacturing Practice for Medical Devices ([2025] No. 107)
2025-11-07
The National Medical Products Administration has revised the Good Manufacturing Practice for Medical Devices. It is hereby released and shall come into force as of November 1, 2026.
-
NMPA Announcement on Optimizing of the Review and Approval Process for Clinical Trials of Innovative Drugs ([2025] No. 86)
2025-10-14
China's top legislator Zhao Leji on Wednesday met with Liberian Senate President Pro Tempore Nyonblee Karnga-Lawrence, who is in Beijing for the Global Leaders' Meeting on Women.
-
Policy Interpretation of the Announcement on Optimizing of the Review and Approval Process for Clinical Trials of Innovative Drugs
2025-10-14
This announcement further refines resource allocation for review and approval, and promotes higher quality and efficiency in clinical development of innovative drugs.
-
Announcement of the National Medical Products Administration on Issuing Measures to Optimize Whole Life-Cycle Regulation in Support of the Innovative Development of High-End Medical Devices ([2025 ]No. 63)
2025-10-14
To thoroughly implement the principles of the Third Plenary Session of the 20th CPC Central Committee and the requirements of the Opinions of the General Office of the State Council on Comprehensively Deepening the Reform of Regulation of Drugs and Medical Devices to Promote the High-Quality Development of the Pharmaceutical Industry (GBF [2024] No. 53), and to improve the review and approval mechanisms, strengthen whole life-cycle regulation, fully support major innovations in high-end medical devices, promote the application of more new technologies, new materials, new processes, and new methods in the healthcare field, better meet public health needs, and enhance China's international competitiveness in high-end medical devices, the National Medical Products Administration hereby proposes the following supporting measures.